Mark Purcell
Stock Analyst at Morgan Stanley
(n/a)
# 4,371
Out of 4,732 analysts
5
Total ratings
n/a
Success rate
-10.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $97.53 | +16.89% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $50.74 | +8.40% | 1 | Jan 23, 2024 | |
| GSK GSK | Initiates: Equal-Weight | $44 | $33.43 | +31.62% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $66.60 | +27.63% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $78.69 | +52.50% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $97.53
Upside: +16.89%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $50.74
Upside: +8.40%
GSK
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $33.43
Upside: +31.62%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $66.60
Upside: +27.63%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $78.69
Upside: +52.50%